|
17 Jun 2022 |
ObsEva Announces European Commission Marketing Authorization for Yselty® (linzagolix), an Oral GnRH Antagonist, for the Treatment of Uterine Fibroids
|
|
17 Jun 2022 |
Cellenkos Receives FDA Clearance of Investigational New Drug (IND) Application for CK0804 as Add on Therapy to Ruxolitinib for the Treatment of Myelofibrosis
|
|
17 Jun 2022 |
LAVA Therapeutics Highlights Encouraging Clinical Updates on Lead Program, LAVA-051, in Chronic Lymphocytic Leukemia and Multiple Myeloma Patients
|
|
17 Jun 2022 |
Sandoz Application for proposed biosimilar adalimumab’s high concentration formulation accepted by EMA
|
|
16 Jun 2022 |
Omega Therapeutics Announces Submission of Investigational New Drug Application for OTX-2002, an Omega Epigenomic Controller, for MYC Driven Hepatocellular Carcinoma
|
|
16 Jun 2022 |
Kymera Therapeutics Doses First Patients in Phase 1 Oncology Trials of STAT3 and IRAKIMiD Degraders KT-333 and KT-413
|
|
16 Jun 2022 |
Phanes Therapeutics announces FDA IND clearance for PT886, an anti-claudin18.2/anti-CD47 bispecific antibody being developed for patients with gastric, gastroesophageal junction, and pancreatic cancers
|
|
16 Jun 2022 |
Vicore announces first human dosed with novel ATRAG, C106
|
|
16 Jun 2022 |
Exelixis and BioInvent Establish Exclusive Option and License Agreement to Develop Novel Antibody-Based Immuno-Oncology Therapies
|
|
16 Jun 2022 |
Genentech Provides Update on Alzheimer’s Prevention Initiative Study Evaluating Crenezumab in Autosomal Dominant Alzheimer’s Disease
|
|
15 Jun 2022 |
Astrocyte Announces Initiation of First-In-Human Phase 1 Study of the Promising Stroke and Traumatic Brain Injury Therapeutic, AST-004
|
|
15 Jun 2022 |
Blue Earth Therapeutics Announces Promising Results of Preclinical Biodistribution and Efficacy Evaluation of 177Lu-rhPSMA-10.1 in Treatment of Prostate Cancer
|
|
15 Jun 2022 |
Boehringer Ingelheim signs Option to Acquire Trutino Biosciences
|
|
15 Jun 2022 |
Clovis Oncology Highlights Phase 1 Data from Ongoing Clinical Studies of Targeted Radiotherapy Candidate FAP-2286 at SNMMI Annual Meeting
|
|
15 Jun 2022 |
MorphoSys and HIBio Enter Into Equity Participation and License Agreements for Felzartamab and MOR210
|
|
14 Jun 2022 |
Veralox Therapeutics Announces Favorable Results of Phase 1 Studies of VLX-1005 in Development for Treatment of Heparin-Induced Thrombocytopenia
|
|
14 Jun 2022 |
D. E. Shaw Research Licenses First-in-Class Therapeutic for Immunological Diseases to Lilly
|
|
14 Jun 2022 |
Curocell announced impressive CR rate in Phase 1 study with anbal-cel, the next generation CD19 CAR-T integrated OVIS™ platform
|
|
14 Jun 2022 |
Regulus Therapeutics Announces First Subject Dosed in Phase 1 Single-Ascending Dose (SAD) Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)
|
|
14 Jun 2022 |
FDA Approves Lilly and Incyte's OLUMIANT® (baricitinib) As First and Only Systemic Medicine for Adults with Severe Alopecia Areata
|
